Experts say manufacturing bottlenecks and material shortages are bigger hurdle to making more vaccines
Shares in pharmaceutical companies fell sharply after the US government threw its weight behind global plans for a patent waiver on Covid-19 vaccines to boost their production and distribution around the world.
Shortly after the US declared its support for the intellectual property (IP) waiver, which still has to be approved by the World Trade Organization, shares in Chinese and American vaccine makers tumbled.
